Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phenobarbital versus levetiracetam as adjunctive therapy for neonatal abstinence syndrome
IRCT20211218053444N2Phase 3Completed
- Sponsor
- Kerman University of Medical Sciences
- Start
- Apr 2022
- Modality
- Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3 trial of phenobarbital and levetiracetam in neonatal abstinence syndrome (NAS) (2 arms), sponsored by Kerman University of Medical Sciences. Primary endpoints: Duration of hospitalization, Duration of treatment and 1 more. Started Apr 2022; status: completed.
02
Drugs
phenobarbitallevetiracetam
03
Conditions
neonatal abstinence syndrome (NAS)
Beyond the preview
Go deeper on IRCT20211218053444N2.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20211218053444N2.